Contact
Positions
Professor
- Organization:
- West Virginia University School of Pharmacy
- Department:
- Pharmaceutical Sciences
- Classification:
- Faculty
Co-Leader Sara Crile Allen and James Frederick Allen Lung Cancer
- Organization:
- West Virginia University WVU Cancer Institute
- Department:
- WVU Cancer Institute Research Programs
- Classification:
- Faculty
Education
- PhD, University of Wisconsin-Madison, 1989
Publications
Top 10 papers:
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+29451776
Short-Term Pulmonary Toxicity Assessment of Pre- and Post-incinerated Organomodified Nanoclay in Mice.
Stueckle TA, Davidson DC, Derk R, Kornberg TG, Battelli L, Friend S, Orandle M, Wagner A, Dinu CZ, Sierros KA, Agarwal S, Gupta RK, Rojanasakul Y, Porter DW, Rojanasakul L.
ACS Nano. 2018 Mar 27;12(3):2292-2310. doi: 10.1021/acsnano.7b07281. Epub 2018 Feb 22.
PMID: 29451776
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+29167312
Inhibition of O-GlcNAcase Sensitizes Apoptosis and Reverses Bortezomib Resistance in Mantle Cell Lymphoma through Modification of Truncated Bid.
Luanpitpong S, Chanthra N, Janan M, Poohadsuan J, Samart P, U-Pratya Y, Rojanasakul Y, Issaragrisil S.
Mol Cancer Ther. 2018 Feb;17(2):484-496. doi: 10.1158/1535-7163.MCT-17-0390. Epub 2017 Nov 22.
PMID: 29167312
https://www.ncbi.nlm.nih.gov/pubmed/28912540/
SOX9 Regulates Cancer Stem-Like Properties and Metastatic Potential of Single-Walled Carbon Nanotube-Exposed Cells.
Voronkova MA, Luanpitpong S, Rojanasakul LW, Castranova V, Dinu CZ, Riedel H, Rojanasakul Y.
Sci Rep. 2017 Sep 14;7(1):11653. doi: 10.1038/s41598-017-12037-8.
PMID: 28912540
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+28912540
Induction of Slug by Chronic Exposure to Single-Walled Carbon Nanotubes Promotes Tumor Formation and Metastasis.
Wang P, Voronkova M, Luanpitpong S, He X, Riedel H, Dinu CZ, Wang L, Rojanasakul Y.
Chem Res Toxicol. 2017 Jul 17;30(7):1396-1405. doi: 10.1021/acs.chemrestox.7b00049. Epub 2017 Jun 20.
PMID: 28598615
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+28513319
Effect of surface functionalizations of multi-walled carbon nanotubes on neoplastic transformation potential in primary human lung epithelial cells.
Stueckle TA, Davidson DC, Derk R, Wang P, Friend S, Schwegler-Berry D, Zheng P, Wu N, Castranova V, Rojanasakul Y, Wang L.
Nanotoxicology. 2017 Jun;11(5):613-624. doi: 10.1080/17435390.2017.1332253. Epub 2017 Jun 2.
PMID: 28513319
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+28288645
Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y.
Mol Cancer. 2017 Mar 14;16(1):63. doi: 10.1186/s12943-017-0633-8
PMID: 28288645
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+27996035
Induction of cancer-associated fibroblast-like cells by carbon nanotubes dictates its tumorigenicity.
Luanpitpong S, Wang L, Castranova V, Dinu CZ, Issaragrisil S, Chen YC, Rojanasakul Y.
Sci Rep. 2016 Dec 20;6:39558. doi: 10.1038/srep39558.
PMID: 27996035
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+27570625
Carcinogenic Potential of High Aspect Ratio Carbon Nanomaterials.
Luanpitpong S, Wang L, Davidson DC, Riedel H, Rojanasakul Y.
Environ Sci Nano. 2016 Jun 1;3(3):483-493. Epub 2016 Apr 6.
PMID: 27570625
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+27422997
Role of mesothelin in carbon nanotube-induced carcinogenic transformation of human bronchial epithelial cells.
He X, Despeaux E, Stueckle TA, Chi A, Castranova V, Dinu CZ, Wang L, Rojanasakul Y.
Am J Physiol Lung Cell Mol Physiol. 2016 Sep 1;311(3):L538-49. doi: 10.1152/ajplung.00139.2016. Epub 2016 Jul 15.
PMID: 27422997
https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+26387547
SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma.
Luanpitpong S, Li J, Manke A, Brundage K, Ellis E, McLaughlin SL, Angsutararux P, Chanthra N, Voronkova M, Chen YC, Wang L, Chanvorachote P, Pei M, Issaragrisil S, Rojanasakul Y.
Oncogene. 2016 Jun 2;35(22):2824-33. doi: 10.1038/onc.2015.351. Epub 2015 Sep 21.
PMID: 26387547
Additional Info
Education:
M.S. (Pharmaceutics) Massachusetts College of Pharmacy and Health Sciences, 1984
B.S. (Pharmacy) Mahidol University, 1982
Research Interests:
- Carcinogenesis and Cancer Treatment
- Nanosafety and Nanomedicine
- Free Radical Biology
- Molecular Pharmacology
Professional Experience:
- Professor, West Virginia University, 2000-
- Allen Lung Cancer Program Leader, Mary Babb Randolph Cancer Center, 2012-
- Acting Chair, Department of Pharmaceutical Sciences, 2009
- Integrated Research Team Leader, WV NanoSAFE, 2010-
- Visiting Professor, Burnham Institute, 2002
- Associate Professor, West Virginia University, 1994-2000
- Guest Scientist, National Institute for Occupational Safety and Health, 1998-
- Visiting Scientist, University of Pittsburgh, 1997
- Assistant Professor, West Virginia University, 1989-1994
Recent/Current Grants:
- Cancer Stem Cells and Nanomaterial Carcinogenicity (NIH R01-ES022968)
- Carbon Nanotube-Induced Fibrosis (NIH R01-HL095579)
- Mechanisms of Death Receptor-Mediated Apoptosis (NIH R01-HL076340)
- Bionanotechnology and Public Safety (NSF EPS-1003907)
- IDeA Network of Research Excellence (NIH P200RR01677)
Teaching:
Professional:
Pharmaceutical Biotechnology
Pharmaceutical Calculations
Pharmaceutics
Graduate:
Drug Discovery and Development
Nanotechnology
Advanced Pharmacology
Cancer Cell Biology
About Yon Rojanasakul
Yon Rojanasakul, Ph.D., is a Professor in the Department of Pharmaceutical Sciences at West Virginia University. Dr. Rojanasakul’s research focuses on understanding the cellular and molecular mechanisms of cancer and fibroproliferative disorders. His research has led to the discovery of key molecular targets and signaling pathways involved in cancer cell death and chemoresistance. The overall goal of his research is to develop more effective strategies for the treatment and diagnosis of cancer and fibrosis. Another key area of Rojanasakul’s research involves nanotechnology with an emphasis on the long-term health effects of engineered nanoparticles. His research develops exposure models and assay methods for nanosafety evaluation, identifies key properties of nanomaterials influencing their bioactivities, and elucidates the cellular and molecular mechanisms of pathogenesis. Dr. Rojanasakul is Principal Investigator of several projects funded by the National Institutes of Health and the National Science Foundation. He is Robert C. Byrd Professor and Benedum Distinguished Scholar at the West Virginia University. He is also a Fellow of the American Association of Pharmaceutical Scientists and Program Leader of the WVU Cancer Center.
Research Program
Sara Crile Allen and James Frederick Allen Lung Cancer